There are three main medication alternatives for use in treating opioid addiction; methadone, buprenorphine, and naltrexone which can be used separately or in combination (e.g., buprenorphine and naltrexone). All three medications are FDA approved and can reduce opioid cravings helping to sever the ties between opioid use and situational/emotional triggers. These medications function by targeting the mu-opioid receptor within the endogenous opioid system, and each has a distinct mechanism of action. Their safety and efficacy profiles vary due to their differing pharmacological, pharmacodynamic, and pharmacokinetic properties. The major limitation to these treatment options is their associated side effects which include abuse and addiction.

Investigators have developed a research program to identify/synthesis a series of novel compounds/molecules integrating the use of ABCN (Hasubanan) and ANO ring systems to produce a new series of pharmacophores with potential analgesic activity. A library of 6144-member, second-generation ABCN hasubanan alkaloid molecules will be identified, and through high-throughput in silico screening, in vitro testing, and in vivo behavioral analyses, 2 or 3 target ligand compounds with the highest treatment potential will be identified for eventual clinical development/trials and commercialization.

Competitive Advantages

•       Potential to realize reduced adverse side effects in treating opioid abuse

•       Synthesis can be performed through the use of a simpler reaction than morphine/related opioids constructed of five rings (ABCNO), with the potential to increase product yields/reduce production costs 

Opportunity

The global opioid disorder market sector was valued at $1.9 billion in 2018 and is anticipated to grow at a robust 10.1% CAGR through 2026. The number of opioid users worldwide has increased by more than any other drug category in recent years.

Rowan University is looking for a partner for further development and commercialization of this technology through a license. The inventor is available to collaborate with interested companies.